Suchergebnisse - "Shiotsu, Shinsuke"

PubPharm (78)

21

Comparison of the prognosis of symptomatic cerebral infarction and pulmonary embolism in patients with advanced non-small cell lung cancer

enthalten in: Cancer medicine | 2023

von Nakamura, R. | Yamada, T. | Tanaka, S. | +13

22

TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma : A Prospective Observational Study

enthalten in: JTO clinical and research reports | 2023

von Katayama, Y. | Yamada, T. | Morimoto, K. | +17

23

Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy : A Prospective Observational Study

enthalten in: JTO clinical and research reports | 2023

von Ishida, M. | Morimoto, K. | Yamada, T. | +13

24

Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR-TKI in non-small cell lung cancer patients with EGFR mutation : A multicenter retrospective study

enthalten in: Thoracic cancer | 2023

von Hata, T. | Sakaguchi, C. | Hirano, K. | +11

25

Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer : Real-World Evidence from a Multicenter Retrospective Study

enthalten in: Cancers | 2023

von Takeda, T. | Yamada, T. | Kunimatsu, Y. | +13

26

High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib

enthalten in: Cancer science | 2023

von Yoshimura, A. | Yamada, T. | Serizawa, M. | +25

27

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer

enthalten in: NPJ precision oncology | 2023

von Katayama, Y. | Yamada, T. | Tanimura, K. | +21

28

Comparison of the prognosis of symptomatic cerebral infarction and pulmonary embolism in patients with advanced non‐small cell lung cancer

enthalten in: Cancer Medicine | 2023

von Nakamura, R. | Yamada, T. | Tanaka, S. | +13

29

High levels of AXL expression in untreated EGFR‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib

enthalten in: Cancer Science | 2023

von Yoshimura, A. | Yamada, T. | Serizawa, M. | +25

30

Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II) : A Single-Arm, Open-Label, Phase 2 Clinical Trial

enthalten in: JTO clinical and research reports | 2022

von Hibino, M. | Hiranuma, O. | Takemura, Y. | +17